320 related articles for article (PubMed ID: 29629216)
1. Novel Systemic Therapies for Advanced Gastric Cancer.
Kim HJ; Oh SC
J Gastric Cancer; 2018 Mar; 18(1):1-19. PubMed ID: 29629216
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune response and immunotherapy in gastric cancer.
Kwak Y; Seo AN; Lee HE; Lee HS
J Pathol Transl Med; 2020 Jan; 54(1):20-33. PubMed ID: 31674166
[TBL] [Abstract][Full Text] [Related]
3. Recent insights into the use of immune checkpoint inhibitors in gastric cancer.
Rodrigues S; Figueiredo C
Porto Biomed J; 2022; 7(1):e162. PubMed ID: 35146175
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer.
Kim M; Jeong JY; Seo AN
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685320
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers along gastric cancer pathogenetic pathways.
Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
[TBL] [Abstract][Full Text] [Related]
14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
[TBL] [Abstract][Full Text] [Related]
16. Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond.
Kim IH
J Gastric Cancer; 2024 Jan; 24(1):29-56. PubMed ID: 38225765
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Precision Treatment in Gastric Cancer.
Petrillo A; Smyth EC
Visc Med; 2020 Oct; 36(5):364-372. PubMed ID: 33178733
[TBL] [Abstract][Full Text] [Related]
18. Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.
Jin H; Li P; Mao C; Zhu K; Chen H; Gao Y; Yu J
Onco Targets Ther; 2020; 13():1751-1756. PubMed ID: 32161470
[TBL] [Abstract][Full Text] [Related]
19. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Alsina M; Moehler M; Hierro C; Guardeño R; Tabernero J
Target Oncol; 2016 Aug; 11(4):469-77. PubMed ID: 26880697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
